- Bristol-Myers wins approval for 1st hepatitis C type 3 drug Updated: Jul-24-15 6:02 pm
TRENTON, New Jersey - An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options - all much more effective but extremely costly - for patients with the liver-destroying virus.
- Federal judge says $50,000 sentence in hepatitis case stays Updated: Jul-24-15 5:05 pm
LAS VEGAS - A federal judge says mistake or not a clinic chief connected to the largest medical office hepatitis C outbreak in Nevada history will pay $50,000 in restitution to overbilled insurers and companies, not $2.2 million prosecutors sought.
- Bristol-Myers says HIV drug gets FDA incentives Updated: Jul-21-15 1:16 pm
NEW YORK - Bristol-Myers said Tuesday that federal regulators will help speed up development for one of its experimental HIV drugs.
- Pricey successor overtakes $1,000-per-pill hepatitis C drug Updated: Jul-13-15 4:20 pm
WASHINGTON - The $1,000 pill for a liver-wasting viral infection that made headlines last year is no longer the favorite of patients and doctors.
- Rise in heroin use, hepatitis C infections worries officials Updated: Jul-06-15 3:53 pm
COLUMBUS, Ohio - The rise of heroin usage and subsequent surge in hepatitis C infections in central Ohio has state health officials considering new ways to combat the issue, including a needle-exchange program.
- Immigrant children given adult dose of hepatitis A vaccine Updated: Jul-04-15 5:23 pm
SAN ANTONIO - About 250 immigrant children were given an adult dose of a hepatitis A vaccine at a Texas detention facility where they were being held with their mothers, according to U.S. Immigration and Customs Enforcement officials.
- Cabell County to have state's 1st syringe exchange program Updated: Jul-02-15 1:10 pm
HUNTINGTON, West Virginia - Cabell County will be the site of West Virginia's first syringe exchange program, which officials say will help reduce infectious diseases within the county's population of intravenous drug-users.